ibotenic acid has been researched along with Atherosclerotic Parkinsonism in 7 studies
Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although it is known that Parkinson's disease results from a loss of dopaminergic neurons in the substantia nigra, the resulting alterations in activity in the basal ganglia responsible for parkinsonian motor deficits are still poorly characterized." | 1.28 | Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. ( Bergman, H; DeLong, MR; Wichmann, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breit, S | 1 |
| Lessmann, L | 1 |
| Unterbrink, D | 1 |
| Popa, RC | 1 |
| Gasser, T | 1 |
| Schulz, JB | 1 |
| Wichmann, T | 3 |
| Bergman, H | 2 |
| DeLong, MR | 3 |
| Lieberman, DM | 1 |
| Corthesy, ME | 1 |
| Cummins, A | 1 |
| Oldfield, EH | 1 |
| Kliem, MA | 1 |
| Wachtel, H | 2 |
| Kunow, M | 2 |
| Löschmann, PA | 2 |
| Lange, KW | 1 |
| Rettig, KJ | 1 |
| Jähnig, P | 1 |
| Honoré, T | 1 |
| Turski, L | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease[NCT04650932] | 10 participants (Anticipated) | Interventional | 2022-10-22 | Recruiting | |||
| NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease[NCT00001929] | Phase 2 | 20 participants | Interventional | 1999-03-31 | Completed | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease[NCT00921128] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-02 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for ibotenic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model.
Topics: Animals; Data Interpretation, Statistical; Electrophysiology; Excitatory Amino Acid Agonists; Iboten | 2006 |
The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Bicuculline; Brain Mapping | 1994 |
Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus.
Topics: Animals; Drug Evaluation, Preclinical; Feasibility Studies; Globus Pallidus; Ibotenic Acid; Infusion | 1999 |
Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carrier Proteins; Dopamine | 2001 |
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamin | 1992 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1991 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |